Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies

The goal of this study is to apply cutting-edge imaging approaches, incorporating machine-learning for pattern recognition and multispectral analysis, to the development and validation of intermediate endpoint biomarkers in benign tissue that characterize the response to 5α-reductase inhibitor chemoprevention as well as the risk of prostate cancer among men with negative biopsies.

Intervention

Placebo, Dutasteride

Condition

Prostate Cancer

Investigators

See list of participating sites